At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Cephalexin Versus Clindamycin in the Empiric, Outpatient Treatment of Suspected Staphylococcal Cutaneous Infections in the Era of Community-associated Methicillin-resistant Staphylococcus Aureus (CA-MRSA)
In Brief
A Phase 4 clinical trial evaluating clindamycin and cephalexin for Staphylococcal Infection and 3 related conditions. Completed, enrolled 200 participants across 1 site.
Detailed Summary
The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). The investigators hypothesize that treatment with cephalexin, a penicillin-like antibiotic to which CA-MRSA would be expected to be resistant, does not result in poorer outcomes than treatment with clindamycin, an antibiotic to which CA-MRSA is most often susceptible.
Study Details
Timeline
Interventions
clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days